Sugi Predict

Sugi Predict / Targets / CKS1B

CKS1B

Cyclin-dependent kinases regulatory subunit 1 · P61024 · CKS1B on Sugi Atlas →

30,000 patent compounds predicted against CKS1B, 13,975 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Selexipag Selexipag (SCHEMBL674122) 1.00 8/20
SCHEMBL618489 SCHEMBL618489 0.50 8/20
Laselipag Laselipag (SCHEMBL676234) 0.77 6/20
SCHEMBL383762 SCHEMBL383762 0.53 5/20
SCHEMBL973782 SCHEMBL973782 0.45 5/20
SCHEMBL616986 SCHEMBL616986 0.49 4/20
SCHEMBL617002 SCHEMBL617002 0.49 4/20
SCHEMBL28868 SCHEMBL28868 0.45 4/20
SCHEMBL173464 SCHEMBL173464 0.44 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL345453) 0.44 4/20
SCHEMBL918377 SCHEMBL918377 0.44 4/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL1238412) 0.43 4/20
SCHEMBL615185 SCHEMBL615185 0.42 4/20
SCHEMBL1103069 SCHEMBL1103069 0.34 4/20
SCHEMBL617577 SCHEMBL617577 0.66 3/20
SCHEMBL530038 SCHEMBL530038 0.61 3/20
SCHEMBL617173 SCHEMBL617173 0.54 3/20
SCHEMBL617174 SCHEMBL617174 0.54 3/20
SCHEMBL526709 SCHEMBL526709 0.53 3/20
SCHEMBL614945 SCHEMBL614945 0.51 3/20

Clinical trials — most relevant to CKS1B by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical and Pharmacoeconomic Assessment of CDK4/6 Inhibitors for Treatment of Breast Cancer in Egypt PHASE4COMPLETED
Effect of Silymarin in Metastatic Colorectal Cancer Patients PHASE3UNKNOWN
A Phase 3 Study Comparing Dinaciclib Versus Ofatumumab in Patients With Refractory Chronic Lymphocytic Leukemia (P07714) PHASE3COMPLETED
CDK 4/6 Inhibitor, Ribociclib, With Adjuvant Endocrine Therapy for ER-positive Breast Cancer PHASE2ACTIVE_NOT_RECRUITING
Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor PHASE2ACTIVE_NOT_RECRUITING
TQB3616 Capsules Combined With Abiraterone Acetate Plus Prednisone in Metastatic Castration-Resistant Prostate Cancer PHASE2UNKNOWN
Bryostatin 1 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer PHASE2COMPLETED
Avelumab, Palbociclib and Axitinib in Advanced RCC PHASE2WITHDRAWN
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE) PHASE1/PHASE2NOT_YET_RECRUITING
Palbociclib and Sasanlimab for the Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC) or Papillary Renal Cell Carcinoma (pRCC) PHASE1/PHASE2RECRUITING
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer PHASE2WITHDRAWN
An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer. PHASE1/PHASE2COMPLETED
Genetic Testing in Guiding Treatment for Patients With Brain Metastases PHASE2ACTIVE_NOT_RECRUITING
Abemaciclib With or Without Atezolizumab for mCRPC PHASE2COMPLETED
Cyclin Dependent Kinase (CDK)4/6 Inhibitor, PD0332991 in Advanced Non-small Cell Lung Cancer NSCLC. PHASE2COMPLETED
AZD1775 for Advanced Solid Tumors PHASE1COMPLETED
Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma PHASE1COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
TSL2109 Capsules in Advanced Solid Tumor Patients: Safety, Tolerability, PK and Preliminary Efficacy PHASE1RECRUITING
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Dose-escalation Study of Oral CX-4945 PHASE1UNKNOWN
Metabolic Signalling in Muscle- and Adipose-tissue Following Insulin Withdrawal and Growth Hormone Injection. nanCOMPLETED
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Study Of Real-World Evidence In Patients Treated With Palbociclib During a 2.5 Years Follow-Up Period nanUNKNOWN
Implementing Patients´ Competence in Oral Breast Cancer Therapy nanUNKNOWN
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics nanUNKNOWN
Studying Biomarkers in Tissue Samples From Young Patients With Acute Myeloid Leukemia Previously Enrolled on Clinical Trial POG-9421 nanCOMPLETED
Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism nanUNKNOWN
Genetic Analysis of Familial Melanoma nanCOMPLETED
Molecular Pathways Related to Short-term Fasting Response nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CKS1B binder may also engage these)

ProteinNameSimilarity
Q0P5A5 — 1.000 Q0P5A5 →
P61025 — 1.000 P61025 →
Q91879 — 0.999 Q91879 →
Q24152 — 0.998 Q24152 →
P55933 — 0.994 P55933 →
P56390 — 0.993 P56390 →
Q6PS57 — 0.993 Q6PS57 →
CKS2 Cyclin-dependent kinases regulatory subunit 2 0.993 landscape →
A2XCH8 — 0.991 A2XCH8 →
A8XMF2 — 0.991 A8XMF2 →
A0L3X0 — 0.990 A0L3X0 →
B7VL66 — 0.990 B7VL66 →
Q2KJI1 — 0.990 Q2KJI1 →
Q4JU00 — 0.989 Q4JU00 →
Q7MWL6 — 0.989 Q7MWL6 →
B7UQ64 — 0.989 B7UQ64 →
C6BYQ6 — 0.989 C6BYQ6 →
Q5GT42 — 0.989 Q5GT42 →
B2RIG0 — 0.989 B2RIG0 →
A4Y6A8 — 0.989 A4Y6A8 →
A1RK88 — 0.988 A1RK88 →
P66198 — 0.988 P66198 →
B8GPB9 — 0.988 B8GPB9 →
O23249 — 0.988 O23249 →
O83756 — 0.988 O83756 →
A5WG70 — 0.988 A5WG70 →
Q3Z2X0 — 0.988 Q3Z2X0 →
B4SVW1 — 0.988 B4SVW1 →
Q046F1 — 0.988 Q046F1 →
P32280 — 0.988 P32280 →